---
title: "NeuroSense prepares Canada new drug submission for PrimeC, targets December 2026 filing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295807509.md"
description: "NeuroSense Therapeutics is preparing a New Drug Submission to Health Canada for its ALS drug PrimeC, with a target filing date of December 2026. This plan follows pre-NDS discussions and utilizes data from the Phase 2b PARADIGM clinical trial and biomarkers."
datetime: "2026-08-13T13:31:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295807509.md)
  - [en](https://longbridge.com/en/news/295807509.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295807509.md)
---

# NeuroSense prepares Canada new drug submission for PrimeC, targets December 2026 filing

-   NeuroSense began preparing a New Drug Submission to Health Canada for ALS drug PrimeC, targeting a December 2026 filing. \* Filing plan follows pre-NDS discussions, drawing on Phase 2b PARADIGM clinical and biomarker data. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN25906) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NRSN.US](https://longbridge.com/en/quote/NRSN.US.md)
- [NRSNW.US](https://longbridge.com/en/quote/NRSNW.US.md)

## Related News & Research

- [NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans](https://longbridge.com/en/news/295817302.md)
- [NeuroSense announces shareholder letter availability](https://longbridge.com/en/news/295808294.md)
- [NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts](https://longbridge.com/en/news/295819565.md)
- [NeuroSense Issues CEO Letter to Shareholders | NRSN Stock News](https://longbridge.com/en/news/295808583.md)
- [11:29 ETNeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada](https://longbridge.com/en/news/295124860.md)